ImmunoCellular Therapeutics (IMUC)., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers.
IMUC’s lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma
IMUC is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.
In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer.
The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.
January 17, 2017
RegMed Investors’ (RMi) closing bell analysis, investors should reflect about what to do next
January 13, 2017
RegMed Investors’ (RMi) closing bell analysis, the week of hype was cut short
January 12, 2017
RegMed Investors’ (RMi) closing bell analysis, 2017 is starting off on a "fractured foot"
January 11, 2017
RegMed Investors’ (RMi) mid-day analysis, the sector gets a message nailed to the door …
January 10, 2017
RegMed Investors’ (RMi) closing bell analysis, some of the “dogs” of sector are getting sheared
January 9, 2017
RegMed Investors’ (RMi) closing bell analysis, the conference week that sets the tone of 2017 or does it?
January 6, 2017
RegMed Investors’ (RMi) closing bell analysis, sector dumps to the downside
January 5, 2017
RegMed Investors’ (RMi) closing bell analysis, weakness ripped the upside a new one
January 4, 2017
RegMed Investors’ (RMi) closing bell analysis: how long has upside pricing been sustainable?
35 companies, 1 interpreter!
Insight, foresight and recommendation
ImmunoCellular Therapeutics (IMUC) -- Always a disappointment having oipened 1/2 at $0.34, cresting to $0.25 on 2/1 closing 2/16 at $0.24. Just another day traders toy ... it's also still in a research mode - stay away.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors